Bioengineered protein drugs market seen reaching $646.93B by 2030

14 hours ago
Bioengineered protein drugs market seen reaching $646.93B by 2030
By AI, Created 12:00 UTC, Nov 20, 2026, AGP -

The global bioengineered protein drugs market is forecast to grow from $435.17 billion in 2025 to $646.93 billion by 2030, driven by chronic disease growth, biologics demand and new drug-development tools. North America led the market in 2025, while the report highlights faster expansion in personalized therapies, biosimilars and AI-enabled development.

Why it matters: - The bioengineered protein drugs market is expanding as demand rises for targeted treatments in oncology, autoimmune disease and rare disease care. - The market’s projected growth points to stronger investment across biologics development, manufacturing and personalized medicine. - Rising chronic disease cases are helping push long-term demand for protein-based therapies.

What happened: - The Business Research Company released its Bioengineered Protein Drugs Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the market will grow from $435.17 billion in 2025 to $468.82 billion in 2026. - The report projects the market will reach $646.93 billion by 2030. - The report puts the market’s 2025-2030 compound annual growth rate at 8.4%. - North America held the largest share of the market in 2025.

The details: - The market’s recent growth has been driven by recombinant DNA technology, rising demand for monoclonal antibodies, advances in cell culture methods, increased biotechnology R&D and the emergence of biosimilars. - The forecast period is supported by rising cases of autoimmune and rare diseases, greater investment in precision medicine, expanded biologics manufacturing capacity, artificial intelligence in drug development and growing demand for personalized therapies. - Key trends identified in the report include personalized protein therapeutics, more advanced protein engineering techniques, growth in contract manufacturing services, improved protein purification technologies and stronger treatments for rare diseases. - Bioengineered protein drugs are created using laboratory techniques that rely on living cells and biological processes centered on protein molecules. - The approach allows precise control over protein mechanical properties and responsiveness to stimuli, while helping maintain high purity and consistent molecular weight. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The company offers a free sample report here. - The full report is available here.

Between the lines: - The forecast suggests bioengineered protein drugs are moving from a niche biotech category toward a broader platform for chronic and high-burden diseases. - The combination of AI, manufacturing scale-up and personalized medicine signals a market shaped as much by production economics as by clinical demand. - The report’s regional breakdown implies the strongest near-term opportunities may come from markets beyond North America as biologics infrastructure expands.

What's next: - The market’s next phase will likely depend on how quickly manufacturers expand biologics capacity and how fast AI tools improve discovery and development. - Demand should continue rising if cancer, autoimmune and rare disease incidence keeps increasing. - The report’s 2030 outlook suggests continued product innovation, more contract manufacturing activity and broader use of precision medicine.

The bottom line: - Bioengineered protein drugs are on track for sustained double-digit-scale dollar growth, with chronic disease burden and next-generation drug development tools driving the market forward.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Economic News Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Economic News Observer

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.